MX2019015226A - Inhibidores de quinasa alk2 que contienen imidazol. - Google Patents
Inhibidores de quinasa alk2 que contienen imidazol.Info
- Publication number
- MX2019015226A MX2019015226A MX2019015226A MX2019015226A MX2019015226A MX 2019015226 A MX2019015226 A MX 2019015226A MX 2019015226 A MX2019015226 A MX 2019015226A MX 2019015226 A MX2019015226 A MX 2019015226A MX 2019015226 A MX2019015226 A MX 2019015226A
- Authority
- MX
- Mexico
- Prior art keywords
- imidazole
- compounds
- pharmaceutically acceptable
- alk2 kinase
- containing inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 3
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 102100034111 Activin receptor type-1 Human genes 0.000 abstract 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 abstract 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen compuestos de la Fórmula I, II, III y IV, y sales de estos aceptables desde el punto de vista farmacéutico. Los compuestos son inhibidores de quinasa ALK2. También se proporcionan composiciones farmacéuticas que comprenden un compuesto de la Fórmula I, II, III o IV, o una sal de este aceptable desde el punto de vista farmacéutico, y métodos que incluyen el uso de los compuestos, o sales de estos aceptables desde el punto de vista farmacéutico, y de las composiciones en el tratamiento y la prevención de distintas enfermedades y afecciones, tales como fibrodisplasia osificante progresiva. (ver Fórmulas).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762520150P | 2017-06-15 | 2017-06-15 | |
PCT/US2018/037503 WO2018232094A1 (en) | 2017-06-15 | 2018-06-14 | Imidazole-containing inhibitors of alk2 kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019015226A true MX2019015226A (es) | 2020-08-03 |
Family
ID=64659499
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015226A MX2019015226A (es) | 2017-06-15 | 2018-06-14 | Inhibidores de quinasa alk2 que contienen imidazol. |
MX2023004309A MX2023004309A (es) | 2017-06-15 | 2019-12-13 | Inhibidores de quinasa alk2 que contienen imidazol. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023004309A MX2023004309A (es) | 2017-06-15 | 2019-12-13 | Inhibidores de quinasa alk2 que contienen imidazol. |
Country Status (19)
Country | Link |
---|---|
US (2) | US11661426B2 (es) |
EP (1) | EP3638229A4 (es) |
JP (2) | JP7257338B2 (es) |
KR (2) | KR102659955B1 (es) |
CN (1) | CN110913855A (es) |
AR (1) | AR112027A1 (es) |
AU (1) | AU2018283053C1 (es) |
BR (1) | BR112019026517A2 (es) |
CA (1) | CA3066164A1 (es) |
CL (1) | CL2019003669A1 (es) |
CO (1) | CO2020000194A2 (es) |
EA (1) | EA202090052A1 (es) |
IL (1) | IL271109B1 (es) |
MA (1) | MA49401A (es) |
MX (2) | MX2019015226A (es) |
PH (1) | PH12019502781A1 (es) |
SG (1) | SG10202112496SA (es) |
TW (1) | TWI833696B (es) |
WO (1) | WO2018232094A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2970205T3 (da) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf |
AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
MX2021000977A (es) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos. |
WO2020068729A1 (en) * | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
AU2020214064B2 (en) * | 2019-01-29 | 2022-10-20 | Shandong Xuanzhu Pharma Co., Ltd. | Hexone glucokinase inhibitor and use thereof |
US20220242870A1 (en) * | 2019-05-17 | 2022-08-04 | Voronoi Inc. | Heterocycle-fused pyrimidine derivative and use thereof |
US20220324874A1 (en) * | 2019-05-21 | 2022-10-13 | Voronoi Inc. | N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer |
GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
AR124442A1 (es) * | 2020-12-21 | 2023-03-29 | Biocryst Pharm Inc | Regímenes de dosificación de inhibidores orales de alk2 |
CA3219966A1 (en) * | 2021-05-25 | 2022-12-01 | Biocryst Pharmaceuticals, Inc. | Imidazole-containing inhibitors of alk2 kinase |
CN116478145B (zh) * | 2022-04-13 | 2024-02-02 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
JP2003514901A (ja) | 1999-11-22 | 2003-04-22 | ワーナー−ランバート・カンパニー | キナゾリン類およびシクリン依存性キナーゼ酵素を阻害するためのその使用 |
NZ522696A (en) * | 2000-06-28 | 2004-08-27 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
KR100876069B1 (ko) | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
WO2004081000A1 (en) | 2003-03-10 | 2004-09-23 | Astrazeneca Ab | Quinazoline derivatives |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
CA2588220A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
DK2041138T3 (da) * | 2006-07-07 | 2014-08-11 | Bristol Myers Squibb Co | Pyrroltriazinkinase-inhibitorer |
US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-AMINOQUINAZOLINE DERIVATIVE |
RU2011116928A (ru) * | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
WO2010143169A2 (en) | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
JP6121658B2 (ja) | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
US9499519B2 (en) | 2012-12-26 | 2016-11-22 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
DK2970205T3 (da) * | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
CN108239071B (zh) | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2018
- 2018-06-13 AR ARP180101628A patent/AR112027A1/es unknown
- 2018-06-14 BR BR112019026517-1A patent/BR112019026517A2/pt unknown
- 2018-06-14 EA EA202090052A patent/EA202090052A1/ru unknown
- 2018-06-14 CN CN201880052585.8A patent/CN110913855A/zh active Pending
- 2018-06-14 JP JP2019568599A patent/JP7257338B2/ja active Active
- 2018-06-14 KR KR1020207001054A patent/KR102659955B1/ko active IP Right Grant
- 2018-06-14 SG SG10202112496SA patent/SG10202112496SA/en unknown
- 2018-06-14 TW TW107120504A patent/TWI833696B/zh active
- 2018-06-14 CA CA3066164A patent/CA3066164A1/en active Pending
- 2018-06-14 MA MA049401A patent/MA49401A/fr unknown
- 2018-06-14 AU AU2018283053A patent/AU2018283053C1/en active Active
- 2018-06-14 US US16/622,816 patent/US11661426B2/en active Active
- 2018-06-14 EP EP18816547.6A patent/EP3638229A4/en active Pending
- 2018-06-14 MX MX2019015226A patent/MX2019015226A/es unknown
- 2018-06-14 IL IL271109A patent/IL271109B1/en unknown
- 2018-06-14 WO PCT/US2018/037503 patent/WO2018232094A1/en active Application Filing
- 2018-06-14 KR KR1020247012786A patent/KR20240063970A/ko active Search and Examination
-
2019
- 2019-12-10 PH PH12019502781A patent/PH12019502781A1/en unknown
- 2019-12-13 MX MX2023004309A patent/MX2023004309A/es unknown
- 2019-12-13 CL CL2019003669A patent/CL2019003669A1/es unknown
-
2020
- 2020-01-09 CO CONC2020/0000194A patent/CO2020000194A2/es unknown
-
2023
- 2023-02-13 US US18/168,055 patent/US20230271975A1/en active Pending
- 2023-04-03 JP JP2023060086A patent/JP2023082149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018283053A1 (en) | 2020-01-16 |
CA3066164A1 (en) | 2018-12-20 |
JP2023082149A (ja) | 2023-06-13 |
WO2018232094A1 (en) | 2018-12-20 |
KR20200028939A (ko) | 2020-03-17 |
MX2023004309A (es) | 2023-05-04 |
SG10202112496SA (en) | 2021-12-30 |
US20220332723A1 (en) | 2022-10-20 |
BR112019026517A2 (pt) | 2020-07-21 |
AU2018283053C1 (en) | 2023-03-02 |
CN110913855A (zh) | 2020-03-24 |
KR102659955B1 (ko) | 2024-04-23 |
EP3638229A4 (en) | 2021-03-03 |
AU2022221581A1 (en) | 2022-09-22 |
US20230271975A1 (en) | 2023-08-31 |
AR112027A1 (es) | 2019-09-11 |
EP3638229A1 (en) | 2020-04-22 |
AU2018283053B2 (en) | 2022-09-08 |
KR20240063970A (ko) | 2024-05-10 |
US11661426B2 (en) | 2023-05-30 |
TWI833696B (zh) | 2024-03-01 |
IL271109B1 (en) | 2024-06-01 |
JP7257338B2 (ja) | 2023-04-13 |
MA49401A (fr) | 2020-04-22 |
EA202090052A1 (ru) | 2020-05-22 |
TW201904958A (zh) | 2019-02-01 |
CL2019003669A1 (es) | 2020-05-22 |
CO2020000194A2 (es) | 2020-04-24 |
PH12019502781A1 (en) | 2020-10-26 |
IL271109A (en) | 2020-01-30 |
JP2020523351A (ja) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
TN2016000501A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors. | |
PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
PH12018500610A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
MX2017013797A (es) | Inhibidor de janus quinasa. | |
PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
MX2015012431A (es) | Pirrol amida como inhibidores. | |
PH12018500626A1 (en) | Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
WO2018044767A3 (en) | Aminopyrimidines as alk inhibitors | |
MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
MX2017000208A (es) | Derivados de quinolizinona como inhibidores de pi3k. | |
MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
MX2021014852A (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2. | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
CR20230597A (es) | Inhibidores de alk2 quinasa que contienen imidazol | |
NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
PH12016502281A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors | |
MA39993A (fr) | Dérivés de pyrrolidine -2,5-dione, compositions pharmaceutiques et procédés pour une utilisation en tant qu'inhibiteursde de ido1 |